Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Remote Decentralized Clinical Trials Could Solve RCT Problems

IMI Project Aims To Establish New Paradigm For Clinical Trials

Executive Summary

A new project by Europe’s Innovative Medicines Initiative that is comparing decentralized and traditional clinical trials was launched just before Janssen announced its own decentralized trial.

You may also be interested in...



EU Remote Trials Project Gets Moving

The COVID-19 pandemic has given a fresh impetus to the ongoing EU project on remote decentralized trials with more appetite for innovative approaches.

Scottish Funding No For Two Orphans As SMC Tries To Catch Up After COVID-19 Backlog

Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.

Cuban COVID-19 Vaccines To Come Under WHO Scrutiny

The Cuban government has approved the country’s home grown COVID-19 vaccine for emergency use in children, while Mexico is poised to authorize another Cuban vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel